<DOC>
	<DOC>NCT02231632</DOC>
	<brief_summary>The purpose of this Phase 2/3 trial is to assess the safety and immunogenicity of Live attenuated Poliomyelitis vaccine (human diploid cell)</brief_summary>
	<brief_title>The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)</brief_title>
	<detailed_description>Live attenuated Poliomyelitis vaccine (human diploid cell) is used for poliovirus prevention in children above 2 years old , Which was developed by Institute of Medical Biology , Chinese Academy of Medical Sciences , based on the other two products : Poliomyelitis Vaccine in Dragee Candy (Monkey Kidney Cell), Live ; and Poliomyelitis（Live）Vaccine (Monkey Kidney Cell),Oral . After its safety been proved in phase 1 clinical trail evaluation , the phase 2/3 trail was started in Guangxi Province, China during 2011-2012. The purpose of this trial is to assess the safety and immunogenicity in healthy children of 2,3 and 4 months old .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Only subjects fulfilling all of the following criteria will be eligible for the study: People aged from 2 months to 4 months old. The subjects or subjects' guardians are able to understand and sign the informed consent The subjects or subjects' guardians allow to comply with the requirements of the protocol Subjects with temperature &lt;=37.0°C on axillary setting The subjects have signed informed consent already The subjects have never been vaccinated with any Poliomyelitis Vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Poliomyelitis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>efficacy</keyword>
</DOC>